Evaluation of the susceptibility trends to meropenem in a nationwide collection of clinical isolates in Japan: a longitudinal analysis from 2002 to 2006

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 3, 2008, Pages 346-350

  Ishii, Yoshikazu ^a   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carbapenems; Drug resistance; Japan; Surveillance; Susceptibility

Indexed keywords

CEFEPIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; HAEMOPHILUS INFLUENZAE; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREND STUDY;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; SENTINEL SURVEILLANCE; THIENAMYCINS;

EID: 45349088072     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.01.022     Document Type: Article

References (22)

1. Arakawa S., Matsui T., Miyazaki S., Hara I., Fujisawa M., Gohji K., Okada H., Teranishi T., and Kamidono S. Empiric breakpoints of antimicrobial agents in urinary tract infection. J. Infect. Chemother. 4 (1998) 128-134
2. Bandoh K., Ueno K., Watanabe K., and Kato N. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study. Clin. Infect. Dis. 16 Suppl 4 (1993) S382-S386
3. Baron E.J. Bacteriology. In: Murray P.R. (Ed). Manual of clinical microbiology. 8th ed. (2003), ASM Press, Washington, DC 268-1036
4. Heilmann K.P., Rice C.L., Miller A.L., Miller N.J., Beekmann S.E., Pfaller M.A., Richter S.S., and Doern G.V. Decreasing prevalence of β-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob. Agents Chemother. 49 (2005) 2561-2564
5. Ishii Y., Tateda K., Yamaguchi K., and the JARS. Evaluation of antimicrobial susceptibility for β-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006). Diagn. Microbiol. Infect. Dis. 60 (2008) 177-183
6. Jacoby G.A., and Munoz-Price L.S. The new β-lactamases. N. Engl. J. Med. 352 (2005) 380-391
7. Jansen W.T., Verel A., Beitsma M., Verhoef J., and Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J. Antimicrob. Chemother. 58 (2006) 873-877
8. Kanazawa K., Nouda H., and Sunagawa M. Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae activity and affinity for penicillin-binding proteins: effect of β-methyl group and C-2 side chain. J. Antibiot. 50 (1997) 162-168
9. Kimura S., Ishii Y., and Yamaguchi K. Evaluation of dipicolinic acid for detection of IMP- or VIM-type 4 metallo-β-lactamase-producing Pseudomonas aeruginosa clinical isolates. Diagn. Microbiol. Infect. Dis. 53 (2005) 241-244
10. Marqué S., Poirel L., Héritier C., Brisse S., Blasco M.D., Filip R., Coman G., Naas T., and Nordmann P. Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe. J Clin Microbiol 43 (2005) 4885-4888
11. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standards-Sixth Edition. M7-A6 vol 23, No. 2 (2003), National Committee for Clinical Laboratory Standards, Wayne, PA
12. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement. M100-S14 (2004), National Committee for Clinical Laboratory Standards, Wayne, PA
13. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Sixth Edition. M11-A6 (2004), National Committee for Clinical Laboratory Standards, Wayne, PA
14. O'Callaghan C.H., Morris A., Kirby S.M., and Shingler A.H. Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob. Agents Chemother. 1 (1972) 283-288
15. Rhomberg P.R., Deshpande L.M., Kirby J.T., and Jones R.N. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC Program (2006). Diagn. Microbiol. Infect. Dis. 59 (2007) 425-432
16. Saito A., Inamatsu T., Okada J., Oguri T., Kanno H., Kusano N., Kumon H., Yamaguchi K., Watanabe A., and Watanabe K. Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released. J. Infect. Chemother. 5 (1999) 223-226
17. Sóki J., Edwards R., Hedberg M., Fang H., Nagy E., Nord C.E., and ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey. Int. J. Antimicrob. Agents 28 (2006) 497-502
18. Sumita Y., and Fukasawa M. Meropenem resistance in Pseudomonas aeruginosa. Chemotherapy 42 (1996) 47-56
19. In: Total Planning Center Osaka (Ed). (2006) Nenn Sekai no Koukinzai Shijyou (2006), Sogo Kikaku Center Osaka Co., Ltd (in Japanese)
20. Turner P.J. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn. Microbiol. Infect. Dis. 60 (2008) 185-192
21. Turner P.J., Greenhalgh J.M., Edwards J.R., and McKellar J. The MYSTIC (meropenem yearly susceptibility test information collection) programme. Int. J. Antimicrob. Agents 13 (1999) 117-125
22. Walsh T.R., Toleman M.A., Poirel L., and Nordmann P. Metallo β-lactamases: the quiet before the storm?. Clin. Microbiol. Rev. 18 (2005) 306-325